Tern Therapeutics, a biotechnology company focused on developing gene therapies for rare diseases, recently launched with $15 million in financing. In announcing the successful close of its Series A financing round, Tern also announced that it has entered into a global licensing agreement with Penn spinout REGENXBIO, co-founded by Dr. James Wilson, MD, PhD, the Rose H. Weiss Orphan Disease Center Director’s Professor at Penn Medicine, for RGX-381 and RGX-181 (now designated TTX-381 and 181, respectively) as mainstays of its initial therapeutic pipeline to treat CLN2 Batten disease. TTX-381 and TTX-181 are novel one-time gene therapy products being developed to treat the ocular and central nervous system symptoms of this disease. Read more here.